What is your experience deploying PCSK9 inhibitors in the clinic, and what are the most reliable and actionable triggers for deploying this program for CV risk reduction? And predictably achieving reimbursement and payor support for this therapy?

What is your experience deploying PCSK9 inhibitors in the clinic, and what are the most reliable and actionable triggers for deploying this program for CV risk reduction? And predictably achieving reimbursement and payor support for this therapy?

What is your experience deploying PCSK9 inhibitors in the clinic, and what are the most reliable and actionable triggers for deploying this program for CV risk reduction? And predictably achieving reimbursement and payor support for this therapy?


Created by

CMEducation Resources IQ&A Cardiovascular Intelligence Zone | The Lipidologist and Atherosclerosis Specialist's Perspective

Presenter

Sergio Fazio, MD

Sergio Fazio, MD

Director, Center for Preventive Cardiology

Director, Center for Preventive Cardiology
Professor of Medicine
Division of Cardiovascular Medicine
School of Medicine
Oregon Health Sciences University (OHSU)
Portland, OR